The government admits hospital pricing needs closer scrutiny

The Centre's acknowledgement of excessive hospital pricing has brought a longstanding problem into sharper focus. The challenge now is to protect patients without compromising access to medicines and medical care.

A hospital bill can contain far more than the cost of a doctor's consultation, a bed or a surgical procedure. Medicines, implants, injections and medical consumables can add substantially to the final amount. For patients undergoing cancer treatment or recovering from major surgery, these expenses can accumulate over weeks or months.

The problem is not simply that healthcare is expensive. It is that patients may have little information about the prices of the products used in their treatment, few opportunities to compare alternatives and limited freedom to question charges when their health is at stake.

Hospital bills are becoming a patient rights issue, as cancer drug mark-ups expose India's healthcare pricing dilemma
(AI generated representative image)

The Union government has acknowledged this concern before the Supreme Court, describing excessive pricing of medicines and consumables by hospitals as malpractice. In an affidavit reported by The Times of India on 23 October, the Centre highlighted mark-ups of 170% to 700% or more on some anti-cancer medicines and 100% to 1,000% or more on certain hospital consumables.

The figures are striking. But the more important question is what they reveal about the relationship between patients, hospitals and the businesses supplying healthcare products.

When patients cannot easily question the bill

A patient buying a medicine from a retail pharmacy may have an opportunity to compare brands, ask about alternatives or visit another shop. That freedom can disappear inside a hospital, particularly during an emergency or an extended course of treatment.

Patients and their families may not know which consumables are medically necessary, whether equivalent products are available or how much the hospital paid for them. When a doctor recommends a procedure and the hospital arranges the supplies, questioning individual prices can feel difficult.

The Centre's affidavit reportedly recognises this imbalance in bargaining power and access to information. It also raises concerns about hospitals purchasing medicines from manufacturers offering higher trade margins and subsequently charging patients the printed maximum retail price (MRP).

This distinction matters. A product sold at its MRP is not necessarily being sold illegally. But a substantial gap between the hospital's procurement price and the amount billed to a patient raises legitimate questions about pricing transparency and the way financial incentives influence purchasing decisions.

The concern extends beyond medicines. Consumables used during surgery, treatment and routine hospital care may appear relatively inexpensive individually, yet their cumulative cost can become significant.

For families paying directly for treatment, the final bill may therefore reflect not just the medical care received, but also the pricing arrangements governing the products used to provide it.

Cancer medicines expose the pricing dilemma

The issue becomes particularly serious when the medicines are required to treat life-threatening illnesses. Cancer patients may need several rounds of treatment, making the cost of medicines a recurring financial burden rather than a one-time expense.

The Centre has announced a proposed intervention to cap trade margins on selected non-scheduled anti-cancer medicines at 30% of their MRP. It expects the measure to reduce prices by 20% to 70% and save patients approximately ₹2,500 crore annually. These are government estimates, not savings already achieved. The medicines covered are to be identified through a separate process.

The Supreme Court, however, has questioned why the response should be confined to cancer medicines. During hearings in September and October, the court drew attention to substantial differences between the prices of medicines and medical supplies at different stages of the supply chain. It pressed the government to consider broader measures.

The Centre has argued that pricing interventions must account for distribution costs and the need to maintain supplies, including in remote areas. The court's scrutiny reflects a competing concern: a pricing system must not leave patients carrying an excessive financial burden simply because they cannot negotiate the cost of treatment.

The problem is also more complicated than setting a single percentage. Medicines, implants and consumables have different costs, supply chains and distribution requirements. A policy that works for one category may not be suitable for another.

A problem that predates the latest intervention

The current debate follows a Supreme Court judgment delivered on 4 March 2025 in Siddharth Dalmia and another versus Union of India and others.

The case concerned allegations that private hospitals compelled patients to buy medicines, devices, implants and consumables from hospital-linked pharmacies at inflated prices. The Court asked state governments to consider appropriate policy measures, while cautioning against interventions that could unreasonably discourage private healthcare providers. It did not rule that the allegations in the petition had been proved.

This distinction is important. The challenge is not to assume that every private hospital engages in malpractice, but to establish clear and enforceable rules that protect patients wherever unreasonable pricing occurs.

There is also a regulatory gap between medicines covered by existing price controls and other products used in hospitals. The Centre's own account acknowledges that more information is needed to understand the scale of the problem and design appropriate interventions.

The Supreme Court's next hearing in the current proceedings was scheduled for 27 October 2026, according to reports published before that date. The outcome of that hearing remains outside the scope of this article.

Transparency must become part of patient care

Price regulation alone may not resolve every problem. Patients also need to know what they are being charged for, whether a prescribed product has a suitable alternative and whether they can obtain it elsewhere without compromising treatment.

Hospitals should be able to explain their charges clearly. Patients should receive itemised bills that distinguish medicines, consumables, procedures and other services. Where a hospital requires a particular product, the medical reason should be understandable to the patient or caregiver.

Regulators, meanwhile, need reliable data on procurement prices and actual billing practices. Without it, they risk introducing rules that are difficult to enforce or that fail to address the largest sources of excessive charges.

The government has acknowledged the problem. The court has demanded a wider examination of medicine pricing. The real test will be whether these developments lead to practical safeguards that patients can see in their bills.

Healthcare is not an ordinary consumer purchase. People often seek it when they have little time, limited information and no easy way to walk away. Protecting them requires more than recognising that prices can be excessive. It requires a system in which charges are transparent, rules are enforceable and the cost of treatment does not become an additional source of distress.

#HealthcareCosts #HospitalOvercharging #HealthcareAffordability #PatientRights #MedicalInflation #CancerTreatment #MedicinePrices #HealthcareReform #SupremeCourtOfIndia #HealthcareInIndia